Cellular senescence in cardiovascular diseases: Potential age-related mechanisms and implications for treatment

Fabiola Olivieri, Rina Recchioni, Fiorella Marcheselli, Angela Marie Abbatecola, Gabriele Santini, Giulia Borghetti, Roberto Antonicelli, Antonio Domenico Procopio

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The aging process is associated with a loss of complexity in the dynamics of physiological systems that reduce the ability to adapt to stress, causing frailty and/or age-related diseases. At the cellular level, proliferative and/or oxidative-stress induced cell senescence associated with a pro-inflammatory state may greatly contribute to age-associated impaired tissue and organ functions. Senescence of endothelial and cardiac cells observed over normal aging, appear to be accelerated in age-related diseases and in particular, in cardiovascular disease (CVD). Although the molecular mechanisms of cellular senescence have been extensively studied, a complete understanding of their role in CVD is still limited. Cardiac, endothelial (EC), vascular smooth muscle (VSMC), leukocytic and stem cells (endothelial progenitor cells (EPC), embryonic stem cells (ESC) and haematopoietic stem cells (HSC)) may play a pivotal role on the maintenance and regeneration of cardiovascular tissue. Age-associated changes of such cells may enhance the risk of developing CVD. The purpose of this review is to illustrate how cellular senescence may affect tissue repair and maintenance toward CVD, focusing on the role played by telomere length and microRNA expression. Finally, interventions aimed at improving the age-related decline in vascular cells during aging and disease, as well as strategies to harness the regenerative capacity of stem cells in CVD will be discussed.

Original languageEnglish
Pages (from-to)1710-1719
Number of pages10
JournalCurrent Pharmaceutical Design
Volume19
Issue number9
Publication statusPublished - 2013

Fingerprint

Cell Aging
Cardiovascular Diseases
Stem Cells
Maintenance
Telomere
Embryonic Stem Cells
Hematopoietic Stem Cells
MicroRNAs
Vascular Smooth Muscle
Smooth Muscle Myocytes
Blood Vessels
Regeneration
Oxidative Stress
Endothelial Cells

Keywords

  • Cellular senescence
  • microRNA
  • Progenitor endothelial cells
  • Telomere length

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

@article{b49dac83afe64c998a5b534580c3b0b0,
title = "Cellular senescence in cardiovascular diseases: Potential age-related mechanisms and implications for treatment",
abstract = "The aging process is associated with a loss of complexity in the dynamics of physiological systems that reduce the ability to adapt to stress, causing frailty and/or age-related diseases. At the cellular level, proliferative and/or oxidative-stress induced cell senescence associated with a pro-inflammatory state may greatly contribute to age-associated impaired tissue and organ functions. Senescence of endothelial and cardiac cells observed over normal aging, appear to be accelerated in age-related diseases and in particular, in cardiovascular disease (CVD). Although the molecular mechanisms of cellular senescence have been extensively studied, a complete understanding of their role in CVD is still limited. Cardiac, endothelial (EC), vascular smooth muscle (VSMC), leukocytic and stem cells (endothelial progenitor cells (EPC), embryonic stem cells (ESC) and haematopoietic stem cells (HSC)) may play a pivotal role on the maintenance and regeneration of cardiovascular tissue. Age-associated changes of such cells may enhance the risk of developing CVD. The purpose of this review is to illustrate how cellular senescence may affect tissue repair and maintenance toward CVD, focusing on the role played by telomere length and microRNA expression. Finally, interventions aimed at improving the age-related decline in vascular cells during aging and disease, as well as strategies to harness the regenerative capacity of stem cells in CVD will be discussed.",
keywords = "Cellular senescence, microRNA, Progenitor endothelial cells, Telomere length",
author = "Fabiola Olivieri and Rina Recchioni and Fiorella Marcheselli and Abbatecola, {Angela Marie} and Gabriele Santini and Giulia Borghetti and Roberto Antonicelli and Procopio, {Antonio Domenico}",
year = "2013",
language = "English",
volume = "19",
pages = "1710--1719",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Cellular senescence in cardiovascular diseases

T2 - Potential age-related mechanisms and implications for treatment

AU - Olivieri, Fabiola

AU - Recchioni, Rina

AU - Marcheselli, Fiorella

AU - Abbatecola, Angela Marie

AU - Santini, Gabriele

AU - Borghetti, Giulia

AU - Antonicelli, Roberto

AU - Procopio, Antonio Domenico

PY - 2013

Y1 - 2013

N2 - The aging process is associated with a loss of complexity in the dynamics of physiological systems that reduce the ability to adapt to stress, causing frailty and/or age-related diseases. At the cellular level, proliferative and/or oxidative-stress induced cell senescence associated with a pro-inflammatory state may greatly contribute to age-associated impaired tissue and organ functions. Senescence of endothelial and cardiac cells observed over normal aging, appear to be accelerated in age-related diseases and in particular, in cardiovascular disease (CVD). Although the molecular mechanisms of cellular senescence have been extensively studied, a complete understanding of their role in CVD is still limited. Cardiac, endothelial (EC), vascular smooth muscle (VSMC), leukocytic and stem cells (endothelial progenitor cells (EPC), embryonic stem cells (ESC) and haematopoietic stem cells (HSC)) may play a pivotal role on the maintenance and regeneration of cardiovascular tissue. Age-associated changes of such cells may enhance the risk of developing CVD. The purpose of this review is to illustrate how cellular senescence may affect tissue repair and maintenance toward CVD, focusing on the role played by telomere length and microRNA expression. Finally, interventions aimed at improving the age-related decline in vascular cells during aging and disease, as well as strategies to harness the regenerative capacity of stem cells in CVD will be discussed.

AB - The aging process is associated with a loss of complexity in the dynamics of physiological systems that reduce the ability to adapt to stress, causing frailty and/or age-related diseases. At the cellular level, proliferative and/or oxidative-stress induced cell senescence associated with a pro-inflammatory state may greatly contribute to age-associated impaired tissue and organ functions. Senescence of endothelial and cardiac cells observed over normal aging, appear to be accelerated in age-related diseases and in particular, in cardiovascular disease (CVD). Although the molecular mechanisms of cellular senescence have been extensively studied, a complete understanding of their role in CVD is still limited. Cardiac, endothelial (EC), vascular smooth muscle (VSMC), leukocytic and stem cells (endothelial progenitor cells (EPC), embryonic stem cells (ESC) and haematopoietic stem cells (HSC)) may play a pivotal role on the maintenance and regeneration of cardiovascular tissue. Age-associated changes of such cells may enhance the risk of developing CVD. The purpose of this review is to illustrate how cellular senescence may affect tissue repair and maintenance toward CVD, focusing on the role played by telomere length and microRNA expression. Finally, interventions aimed at improving the age-related decline in vascular cells during aging and disease, as well as strategies to harness the regenerative capacity of stem cells in CVD will be discussed.

KW - Cellular senescence

KW - microRNA

KW - Progenitor endothelial cells

KW - Telomere length

UR - http://www.scopus.com/inward/record.url?scp=84876707441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876707441&partnerID=8YFLogxK

M3 - Article

C2 - 23061728

AN - SCOPUS:84876707441

VL - 19

SP - 1710

EP - 1719

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 9

ER -